Telangana is now betting big on advanced therapeutics, frontier R&D, and a globally integrated innovation ecosystem to transform the state into a world-class life sciences hub over the next decade.

 

The state has launched its Next-Gen Life Sciences Policy 2026–30 at the World Economic Forum Annual Meeting in Davos, signaling its intent to become a global hub for healthcare innovation, advanced therapeutics, and sustainable bio-manufacturing.

 

The policy marks a shift from scale-driven manufacturing to value-led, innovation-powered growth, with Telangana aiming to rank among the top five life sciences clusters worldwide by 2030. Targets include USD 25 billion in investments, 500,000 high-quality jobs, and deeper integration into global life sciences value chains.

 

Global pharma and biotech giants—including Amgen, Sanofi, Bristol Myers Squibb, and Lilly—have already set up or expanded R&D, digital, and global capability centres in Hyderabad, reflecting confidence in the state’s talent and infrastructure.

 

The policy represents a strategic push from being indispensable in global supply chains to becoming a global originator of advanced therapies and platforms.

 

Unveiling the policy, Chief Minister Revanth Reddy said, "We are building one of the world’s most trusted and transformational biosciences ecosystems—driving global health impact from Telangana. The policy’s global unveiling at Davos reflects Telangana’s conviction that the next phase of growth in life sciences will be driven by cross-border collaboration, global capital, and shared innovation agendas."

 

The state has already attracted Rs. 73,000 crore in investment over the past two years. 

 

Minister for IT & Industries D Sridhar Babu said, "With the launch of new policy, we are now aiming higher to attract Rs. 2 Lakh crore over the next 5 years. The policy prioritizes frontier science and advanced manufacturing platforms, including cell and gene therapies, peptides, precision fermentation, and other next-generation modalities. 

 

"It strengthens the broader ecosystem across clinical research, pharma services, diagnostics, medical electronics and digital health—positioning Telangana as a preferred destination for global life sciences hubs."

 

Sanjay Kumar, Special Chief Secretary of Industries & Commerce, added, "The Policy builds on the strong foundation and spirit of innovation. The policy is not merely a framework; it is designed to accelerate the adoption of breakthrough technologies such as AI, digital health, and next generation therapeutics, while nurturing skilled talent. 

 

"A defining reform is the recognition of R&D units as full-fledged industrial enterprises, allowing them equal access to incentives and reinforcing the State’s commitment to innovation and high-value scientific activity."

 

Shakthi M Nagappan, CEO of Telangana Life Sciences, highlighted, "Focused on frontier R&D, sustainable manufacturing, talent development, and a robust startup-to-scale-up pipeline, the policy strengthens Telangana’s integration into the global life sciences value chain. 

 

"A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore (US$ 100 million), will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics. Another key initiative proposed is the establishment of the Telangana School of Life Sciences, a university of global excellence focused on research, education, and future-ready talent development."

 

 

Frontier R&D and Advanced Manufacturing: Promoting biologics, cell & gene therapy, mRNA platforms, CRISPR, peptides, and precision fermentation.

 

Clinical Research: Faster approvals, disease-specific registries, and the Clinical Innovation Sandbox.

 

Pharma Services: Scaling CRO/CDMO ecosystem from USD 2 billion to USD 10 billion.

 

Diagnostics & Medical Electronics: Creating a robust R&D and manufacturing hub.

 

Global Value & Innovation Centres: Attracting GCCs for AI, digital health, and advanced analytics.

 

Precision Medicine: Developing privacy-compliant clinical registries and digital health platforms.

 

Implementation will be backed by world-class infrastructure: Green Pharma City with net-zero practices and zero liquid discharge; Ten Pharma Villages along the Outer Ring Road (1,000–3,000 acres each); Expansion of Genome Valley with multi-tenant labs and flatted factories; and Medical Devices Park upgrades with plug-and-play R&D facilities.

 

The policy also emphasizes talent development, regulatory streamlining through TG-iPASS, and a Life Sciences Innovation Fund of up to INR 1,000 crore to support startups, scale-ups, and translational research.